دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Recognizing the Effects and Disparities of Pediatric Hidradenitis Suppurativa
Joslyn S. Kirby, MD, MS, MEd; Andrea L. Zaenglein, MD
doi : 10.1001/jamadermatol.2020.5434
JAMA Dermatol. 2021;157(4):379-380
In 2015, hidradenitis suppurativa (HS) was deemed a rare disease that was reported to affect fewer than 200?000 adults in the US, thus allowing adalimumab (Humira; AbbVie) to gain orphan drug approval for the treatment of moderate to severe disease in adults.1 Three years later in 2018, adalimumab was granted orphan drug approval for moderate to severe HS in adolescents (age 12-17 years), a group thought to be even less frequently affected by HS compared with adults.1 However, in the same year, Ingram et al2 reported updated epidemiological data on the prevalence of HS, with an estimated overall prevalence of HS at 0.77% in a Western population. The data by Ingram et al2 confirmed the experience of many dermatologists, that HS is not uncommon, but rather unseen.
Importance of Standardized Nomenclature to Advance Hidradenitis Suppurativa Research and Clinical Care
Haley B. Naik, MD, MHSc
doi : 10.1001/jamadermatol.2020.5466
JAMA Dermatol. 2021;157(4):381-383
Hidradenitis suppurativa (HS) is a clinically heterogeneous disease with few effective treatments.1 While clinical examination forms the basis for HS diagnosis and evaluation, HS clinical heterogeneity poses substantial challenges for assessing disease severity, activity, and treatment response.2 Efforts to accurately quantify HS severity and treatment response have resulted in the development of more than 30 investigator- and patient-reported outcome measures, several of which are unvalidated and some of which are unresponsive to changes in disease, that have been used in more than 12 randomized clinical trials, thus limiting comparisons of evidence across trials.3
Stigmatizing Alopecia—Perspectives of a Bald Dermatologist
Carolyn Goh, MD
doi : 10.1001/jamadermatol.2020.5731
JAMA Dermatol. 2021;157(4):383-384
Stigma, a powerful term defined as the situation of the individual who is “disqualified from full social acceptance,”1 can relate to a multitude of characteristics. Put another way, stigma is “a social construction that involves at least two fundamental components: (1) the recognition of difference based on some distinguishing characteristic or ‘mark’; and (2) a consequent devaluation of the person.”2(p3) Most skin diseases are potentially stigmatizing because they are so visible.3 Yet skin diseases, especially hair loss, are often deemed cosmetic, which can lead to undertreatment by clinicians, lack of insurance coverage, and substantial psychological and financial burdens.4
Hidradenitis Suppurativa in the Pediatric PopulationAn International, Multicenter, Retrospective, Cross-sectional Study of 481 Pediatric Patients
Carmen Liy-Wong, MD; Mary Kim, MD; A. Yasmine Kirkorian, MD
doi : 10.1001/jamadermatol.2020.5435
JAMA Dermatol. 2021;157(4):385-391
This cross-sectional study examines the demographics, clinical features, treatment, associated comorbidities, and outcomes in a large cohort of pediatric patients with hidradenitis suppurativa.
Evaluation of Stigma Toward Individuals With Alopecia
Andrew Creadore, BS; Priya Manjaly, BA; Sara J. Li, BS
doi : 10.1001/jamadermatol.2020.5732
JAMA Dermatol. 2021;157(4):392-398
This cross-sectional study assesses the prevalence and magnitude of layperson stigma toward individuals with varying degrees of alopecia.
An Evaluation of the Performance of Current Morphea Subtype Classifications
Smriti Prasad, MD, MPH; Jane L. Zhu, BA; Kaila Schollaert-Fitch, BS
doi : 10.1001/jamadermatol.2020.5809
JAMA Dermatol. 2021;157(4):399-405
This cross-sectional study uses data from 2 patient cohorts to evaluate how frequently the commonly used morphea classification systems categorize patients with morphea into clinically relevant subtypes.
Differences in Outpatient Dermatology Encounter Work Relative Value Units and Net Payments by Patient Race, Sex, and Age
Lauren A. V. Orenstein, MD; Malik M. Nelson, BS; Zachary Wolner, MD
doi : 10.1001/jamadermatol.2020.5823
JAMA Dermatol. 2021;157(4):406-412
This cross-sectional study examines the use of work relative value unit to calculate dermatologist productivity and compensation according to the demographic characteristics of patients.
Association of Patient Mental Health Status With the Level of Agreement Between Patient and Physician Ratings of Psoriasis Severity
Ewan Carr, PhD; Satveer K. Mahil, PhD; Anamaria Brailean, PhD
doi : 10.1001/jamadermatol.2020.5844
JAMA Dermatol. 2021;157(4):413-420
This cohort study examines the ratings of physicians compared with the ratings of patients on the severity of psoriasis in patients with depression and anxiety.
Mixed Individual-Aggregate Data on All-Cause Mortality in Bullous PemphigoidA Meta-analysis
Billal Tedbirt, MD; André Gillibert, MD; Emilie Andrieu, MD
doi : 10.1001/jamadermatol.2020.5598
JAMA Dermatol. 2021;157(4):421-430
This meta-analysis estimates the 1-year standardized mortality ratio among patients with bullous pemphigoid.
Mycosis Fungoides in Children and AdolescentsA Systematic Review
Joon Min Jung, MD; Dong Jun Lim, MD; Chong Hyun Won, MD, PhD
doi : 10.1001/jamadermatol.2021.0083
JAMA Dermatol. 2021;157(4):431-438
This systematic review assesses the clinical features, immunophenotypes, various treatment options, and prognosis of mycosis fungoides in children and adolescents.
A Global eDelphi Exercise to Identify Core Domains and Domain Items for the Development of a Global Registry of Alopecia Areata Disease Severity and Treatment Safety (GRASS)
Dmitri Wall, MBBCh, BAO, MSc Health Informatics; Nekma Meah, MBChB; Katherine York, MBBCh
doi : 10.1001/jamadermatol.2020.5839
JAMA Dermatol. 2021;157(4):439-448
This review seeks to reach international consensus regarding the core domains and data items required to build a network of patient registries to monitor real-world demographics and outcomes of alopecia areata.
Global Harmonization of Morphological Definitions in Hidradenitis Suppurativa for a Proposed Glossary
John W. Frew, MBBS, MMed, MSc; Michelle Anne Lowes, MBBS, PhD; Noah Goldfarb, MD
doi : 10.1001/jamadermatol.2020.5467
JAMA Dermatol. 2021;157(4):449-455
This consensus statement establishes and validates consensus definitions for typical morphological findings in hidradenitis suppurativa lesions.
Koplik Spots
Puravoor Jayasree, MD, DNB; Karalikkattil T. Ashique, MBBS, DDVL, PGDHS; Feroze Kaliyadan, MD, DNB
doi : 10.1001/jamadermatol.2020.4397
JAMA Dermatol. 2021;157(4):456
This case report describes multiple discrete 2- to 3-mm pinpoint yellow papules and blue-white spots with peripheral erythematous rings on the right side that were opposite the second molar.
Telangiectases in Systemic Sclerosis
Rebecca Jacobson, BM; Ritesh Agnihothri, MD; Anna Haemel, MD
doi : 10.1001/jamadermatol.2020.4831
JAMA Dermatol. 2021;157(4):457
This case report describes a woman in her 30s with puffy fingers, nailfold capillary changes, and abundant mat telangiectases scattered on the upper trunk, arms, and hands.
Multiple, Tender Perianal Ulcers in a Young Woman
Nelson Ugwu, BS; Anjela Galan, MD; Caroline A. Nelson, MD
doi : 10.1001/jamadermatol.2020.5764
JAMA Dermatol. 2021;157(4):458-459
A woman in her late 30s presents with a 4-day history of perianal pain. Her medical history includes systemic lupus erythematosus, antiphospholipid antibody syndrome, and external hemorrhoids, as well as a deceased donor kidney transplant 6 months earlier. Her laboratory test results were notable for elevated creatinine and thrombocytopenia, and 1 day later she developed diarrhea. Antigen and toxin testing for Clostridium difficile was positive. What is your diagnosis?
A “Turkey Ear” Persisting for 5 Decades
Nir Tsur, MD; Aviv Barzilai, MD, MSc; Nadav Astman, MD, PhD
doi : 10.1001/jamadermatol.2020.5832
JAMA Dermatol. 2021;157(4):460-461
A woman in her 50s presented with an edematous, massively enlarged right auricle; histopathologic evaluation revealed noncaseating granulomatous dermatitis. What is your diagnosis?
Skin Biopsy Equipment Availability Across 7 Low-Income CountriesA Cross-Sectional Study of 6053 Health Facilities
Devon E. McMahon, BA; Miriam Laker-Oketta, MD, MSc; Gregory A. Peters, MD
doi : 10.1001/jamadermatol.2020.5851
JAMA Dermatol. 2021;157(4):462-464
This cross-sectional study characterizes the availability of skin biopsy equipment in 7 low-income countries using nationally representative facility data.
Expert Knowledge, Attitudes, and Practices in Management of Hidradenitis Suppurativa Pain
Mark J. Jedrzejczak, BS; John R. Ingram, MA, MSc, DM, MRCP(Derm); Michelle A. Lowes, MBBS, PhD
doi : 10.1001/jamadermatol.2020.5857
JAMA Dermatol. 2021;157(4):464-466
This cross-sectional survey characterizes the knowledge, attitudes, and practices of international experts in the management of pain in patients with hidradenitis suppurativa.
Expert Knowledge, Attitudes, and Practices in Management of Hidradenitis Suppurativa Pain
Mark J. Jedrzejczak, BS; John R. Ingram, MA, MSc, DM, MRCP(Derm); Michelle A. Lowes, MBBS, PhD
doi : 10.1001/jamadermatol.2020.5857
JAMA Dermatol. 2021;157(4):464-466
This cross-sectional survey characterizes the knowledge, attitudes, and practices of international experts in the management of pain in patients with hidradenitis suppurativa.
Inhibition of Progression of Acrodermatitis Continua of Hallopeau With Baricitinib
Guang-Ming Han, PhD, MD; Wan-Shan Yang, MD; Bin Yang, MD
doi : 10.1001/jamadermatol.2021.0045
JAMA Dermatol. 2021;157(4):466-468
This case report describes pustules beneath the fingernails that were accompanied by redness and swelling of distal interphalangeal joints.
Subcutaneous Fat Necrosis During Nivolumab Therapy for Metastatic Melanoma
Jolanta Pach, BA; Brianna Olamiju, BA; Sarah Weiss, MD
doi : 10.1001/jamadermatol.2021.0058
JAMA Dermatol. 2021;157(4):468-469
This case report describes a 78-year-old woman with multiple subcutaneous nodules on her legs, left breast, and left arm that evolved into larger areas of lipoatrophy.
JAMA Dermatology
empty
doi : 10.1001/jamadermatol.2020.3872
JAMA Dermatol. 2021;157(4):375
Mission Statement: JAMA Dermatology publishes information concerning the skin, its diseases, and their treatment. Its mission is to explicate the structure and function of the skin and its diseases and the art of using this information to deliver optimal medical and surgical care to the patient. We attempt to enhance the understanding of cutaneous pathophysiology and improve the clinician’s ability to diagnose and treat skin disorders. This journal has a particular interest in publishing clinical and laboratory studies that reveal new information pertinent to the interests and needs of the medical dermatologist, dermatologic surgeon, and all those concerned with state-of-the-art care of cutaneous disease. We believe that knowledge derived from well-designed clinical trials and studies of cost-effectiveness are especially important for improving the practice of dermatology. Studies that increase the understanding of the outcome of treatment or the means by which the burden of dermatologic disease can be measured and reduced to promote the health of patients with skin disease will receive special priority. The journal regularly publishes reports on clinical investigations, editorials, and reviews. It also features reports and discussions on clinicopathologic correlations; clinical disorders of unique didactic value; pharmacologic, medical and surgical therapeutics; and ethical, moral, socioeconomic, and political issues.
